Hormone FDA Approved

Pasireotide

An FDA-approved somatostatin analog marketed as Signifor, used in Cushing's disease and related endocrine settings.

Somatostatin AnalogFDA ApprovedCushing's DiseaseEndocrine

Also referenced as: Signifor, Signifor LAR

Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Category
Hormone

This profile is grouped by its dominant research and market lane, not by vendor shelf placement.

Aliases
2

Signifor, Signifor LAR

Signal depth
High

FDA label signal · 87 trials · 760 PubMed results

Established
Research evidence

Pasireotide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Pasireotide has 65 name-matched clinical trials (highest phase: Phase 4) and 760 PubMed-indexed publications and holds an FDA drug label. 31 trials have posted results.

FAERS (approved drug): 467
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals
PHASE4 · Randomized Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies PHASE4 · Randomized Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly PHASE4 · Randomized HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications New England Journal of Medicine · 641 citations A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease New England Journal of Medicine · 438 citations Pasireotide for Postoperative Pancreatic Fistula The Lancet Diabetes & Endocrinology · 402 citations Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What pasireotide is

Pasireotide is an FDA-approved somatostatin analog marketed as Signifor and Signifor LAR.

Why it matters

It gives the library another important approved endocrine peptide and helps distinguish the different drugs within the somatostatin-analog family.

Regulatory context

Pasireotide is FDA approved in the United States for specific endocrine indications.

Practical reading note

Even peptides in the same broad family can differ a lot in real-world indication, receptor profile, and clinical use.